{"altmetric_id":1517019,"counts":{"readers":{"mendeley":135,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["147927835252207"],"posts_count":2},"googleplus":{"unique_users_count":1,"unique_users":["Multipharma Group"],"posts_count":1},"news":{"unique_users_count":9,"unique_users":["bioportfolio","lainformacion_com","ad_hoc_news","medical_news_today","today_topics","medpage_today","cnbc","bloomberg","yahoo_finance_usa"],"posts_count":12},"total":{"posts_count":36},"twitter":{"unique_users_count":15,"unique_users":["PHB92","ARD_BMJ","Drbeckyg","biosimilarz","philipcrobinson","k_masuko","LS_Medical","Darshanjagannat","AnnemarieVtW","ELECTOR_eHealth","chandini_rao","ElenaNikiUK","nostrobardo","psufka","PhilipGardiner"],"posts_count":21}},"selected_quotes":["The #AS PK study contributing to infliximab biosimliar approval, marketed this week in Europe","PLANETAS: RCT of biosimilar shows equivalence with infliximab in AS FFT #23687260 #Rheumedu #spondylitis","Missed It? CT-P13 and innovator Infliximab in patients with Ankylosing Spondylitis: the PLANETAS study. #ARD","@Petrosn4 Could be , but CT-P13 (infliximab) achieved 90% CI 95%-109% in 250 AS patients 1:1 CT-P13:Remicade;"],"citation":{"abstract":"To compare the pharmacokinetics (PK), safety and efficacy of innovator infliximab (INX) and CT-P13, a biosimilar to INX, in patients with active ankylosing spondylitis (AS).","abstract_source":"pubmed","altmetric_jid":"4f6fa60b3cf058f610006a32","authors":["Won Park","Pawel Hrycaj","Slawomir Jeka","Volodymyr Kovalenko","Grygorii Lysenko","Pedro Miranda","Helena Mikazane","Sergio Gutierrez-Ure\u00f1a","MieJin Lim","Yeon-Ah Lee","Sang Joon Lee","HoUng Kim","Dae Hyun Yoo","J\u00fcrgen Braun"],"doi":"10.1136\/annrheumdis-2012-203091","first_seen_on":"2013-05-29T08:55:01+00:00","issns":["1468-2060","0003-4967"],"issue":"10","journal":"Annals of the Rheumatic Diseases","last_mentioned_on":1458300473,"links":["http:\/\/ard.bmj.com\/content\/early\/2013\/05\/16\/annrheumdis-2012-203091.short","http:\/\/ard.bmj.com\/content\/72\/10\/1605.full.pdf","http:\/\/m.ard.bmj.com\/content\/72\/10\/1605.full","http:\/\/ard.bmj.com\/content\/early\/2013\/05\/16\/annrheumdis-2012-203091.full","http:\/\/ard.bmj.com\/content\/early\/2013\/05\/16\/annrheumdis-2012-203091.full?utm_content=bufferd3908&utm_medium=social&utm_source=facebook.com&utm_campaign=buffer","http:\/\/ard.bmj.com\/content\/72\/10\/1605.full.pdf+html","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=park+w+jeka+s+miranda+p+safety+ct-p13+ankylosing"],"pdf_url":"http:\/\/ard.bmj.com\/content\/early\/2013\/05\/16\/annrheumdis-2012-203091.full.pdf","pmid":"23687259","pubdate":"2013-05-16T00:00:00+00:00","publisher":"BMJ Publishing Group Ltd and European League Against Rheumatism","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Immunology","scheme":"era"},{"name":"Public Health And Health Services","scheme":"era"}],"scopus_subjects":["Life Sciences","Medicine","Health Sciences","Immunology and Microbiology","Biochemistry, Genetics and Molecular Biology"],"subjects":["rheumatology"],"title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","type":"article","volume":"72","mendeley_url":"http:\/\/www.mendeley.com\/research\/randomised-doubleblind-multicentre-parallelgroup-prospective-study-comparing-pharmacokinetics-safety"},"altmetric_score":{"score":79.95,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":79.95},"context_for_score":{"all":{"total_number_of_other_articles":8021223,"mean":6.7870651379511,"rank":102303,"this_scored_higher_than_pct":98,"this_scored_higher_than":7918907,"rank_type":"exact","sample_size":8021223,"percentile":98},"similar_age_3m":{"total_number_of_other_articles":122697,"mean":6.832169019365,"rank":1664,"this_scored_higher_than_pct":98,"this_scored_higher_than":121031,"rank_type":"exact","sample_size":122697,"percentile":98},"this_journal":{"total_number_of_other_articles":3160,"mean":7.8726432415321,"rank":44,"this_scored_higher_than_pct":98,"this_scored_higher_than":3116,"rank_type":"exact","sample_size":3160,"percentile":98},"similar_age_this_journal_3m":{"total_number_of_other_articles":115,"mean":6.1102280701754,"rank":1,"this_scored_higher_than_pct":99,"this_scored_higher_than":114,"rank_type":"exact","sample_size":115,"percentile":99}}},"demographics":{"poster_types":{"member_of_the_public":10,"researcher":1,"practitioner":3,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":10,"Science communicators (journalists, bloggers, editors)":1,"Practitioners (doctors, other healthcare professionals)":3,"Scientists":1}},"mendeley":{"by_status":{"Unspecified":3,"Professor > Associate Professor":3,"Researcher":26,"Student  > Doctoral Student":9,"Student  > Ph. D. Student":17,"Student  > Postgraduate":9,"Other":19,"Student  > Master":23,"Student  > Bachelor":15,"Lecturer":6,"Lecturer > Senior Lecturer":2,"Professor":3},"by_discipline":{"Medicine and Dentistry":76,"Social Sciences":1,"Physics and Astronomy":1,"Psychology":3,"Unspecified":10,"Environmental Science":1,"Pharmacology, Toxicology and Pharmaceutical Science":7,"Arts and Humanities":1,"Engineering":2,"Chemistry":3,"Economics, Econometrics and Finance":2,"Agricultural and Biological Sciences":19,"Business, Management and Accounting":2,"Nursing and Health Professions":2,"Biochemistry, Genetics and Molecular Biology":5}}},"geo":{"twitter":{"FR":1,"NZ":1,"GB":4,"AU":1,"JP":1,"NL":1,"DK":1,"US":1},"mendeley":{"SG":1,"NL":1,"TR":1,"BE":1,"JP":1,"FI":1,"EG":1,"BR":2,"GB":2,"IT":1,"DE":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/PHB92\/statuses\/376623412585566208","license":"public","rt":["philipcrobinson"],"citation_ids":[1517019],"posted_on":"2013-09-08T08:29:53+00:00","author":{"name":"Philippe Brissaud","url":"http:\/\/www.bio-therapy.net","image":"https:\/\/pbs.twimg.com\/profile_images\/1902817121\/Philippe_normal.jpg","description":"M\u00e9decin Interniste\r\nJournaliste m\u00e9dical","id_on_source":"PHB92","tweeter_id":"109366328","geo":{"lt":48.8846,"ln":2.26965,"country":"FR"},"followers":1311},"tweet_id":"376623412585566208"},{"url":"http:\/\/twitter.com\/ARD_BMJ\/status\/385032390780805120","license":"public","citation_ids":[1517019],"posted_on":"2013-10-01T13:24:10+00:00","author":{"name":"ARD","url":"http:\/\/ard.bmj.com","image":"https:\/\/pbs.twimg.com\/profile_images\/784372806297460737\/0G3PFep__normal.jpg","description":"ARD is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange. Top impact factor in the rheumatology field","id_on_source":"ARD_BMJ","tweeter_id":"138744646","geo":{"lt":null,"ln":null},"followers":3203},"tweet_id":"385032390780805120"},{"url":"https:\/\/twitter.com\/Drbeckyg\/status\/534333603208232960","license":"datasift","citation_ids":[1517019],"posted_on":"2014-11-17T13:13:53+00:00","author":{"name":"Rebecca Grainger","image":"https:\/\/pbs.twimg.com\/profile_images\/533374855618392066\/qpk3J6yn_normal.jpeg","description":"Rheumatologist NZ | Arthritis | CHIA | eHealth and mHealth | medical education | yogi | \u2615\ufe0f| passionate Wellingtonian |ATMO","id_on_source":"Drbeckyg","tweeter_id":"184122949","geo":{"lt":-41.28664,"ln":174.77557,"country":"NZ"},"followers":1236},"tweet_id":"534333603208232960"},{"url":"https:\/\/twitter.com\/biosimilarz\/status\/500226786345889792","license":"datasift","citation_ids":[1517019],"posted_on":"2014-08-15T10:25:34+00:00","author":{"name":"Biosimilarz","url":"http:\/\/www.biosimilarz.com","image":"https:\/\/pbs.twimg.com\/profile_images\/907242680903622658\/qKOJX8n0_normal.jpg","description":"Musings on all things #biosimilar with some personal stuff thrown in. All words are my own!","id_on_source":"biosimilarz","tweeter_id":"239982538","geo":{"lt":51.19242,"ln":0.27532,"country":"GB"},"followers":1829},"tweet_id":"500226786345889792"},{"url":"http:\/\/twitter.com\/ARD_BMJ\/statuses\/375530038075985920","license":"public","citation_ids":[1517019],"posted_on":"2013-09-05T08:05:12+00:00","author":{"name":"ARD","url":"http:\/\/ard.bmj.com","image":"https:\/\/pbs.twimg.com\/profile_images\/784372806297460737\/0G3PFep__normal.jpg","description":"ARD is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange. Top impact factor in the rheumatology field","id_on_source":"ARD_BMJ","tweeter_id":"138744646","geo":{"lt":null,"ln":null},"followers":3203},"tweet_id":"375530038075985920"},{"url":"http:\/\/twitter.com\/ARD_BMJ\/statuses\/375534190000754688","license":"public","citation_ids":[1517019],"posted_on":"2013-09-05T08:21:42+00:00","author":{"name":"ARD","url":"http:\/\/ard.bmj.com","image":"https:\/\/pbs.twimg.com\/profile_images\/784372806297460737\/0G3PFep__normal.jpg","description":"ARD is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange. Top impact factor in the rheumatology field","id_on_source":"ARD_BMJ","tweeter_id":"138744646","geo":{"lt":null,"ln":null},"followers":3203},"tweet_id":"375534190000754688"},{"url":"https:\/\/twitter.com\/philipcrobinson\/status\/376522561107943424","license":"public","citation_ids":[1517019],"posted_on":"2013-09-08T01:49:08+00:00","author":{"name":"Philip Robinson","url":"http:\/\/brisbanerheumatology.com.au","image":"https:\/\/pbs.twimg.com\/profile_images\/741158167237775360\/Umv4cQ26_normal.jpg","description":"Rheumatologist; tweet health, healthcare, medicine, science & rheumatology mostly.","id_on_source":"philipcrobinson","tweeter_id":"246959615","geo":{"lt":-27.46794,"ln":153.02809,"country":"AU"},"followers":2225},"tweet_id":"376522561107943424"},{"url":"http:\/\/twitter.com\/k_masuko\/statuses\/376525070140575744","license":"public","rt":["philipcrobinson"],"citation_ids":[1517019],"posted_on":"2013-09-08T01:59:06+00:00","author":{"name":"Kayo Masuko MD","url":"http:\/\/community.frontiersin.org\/people\/KayoMasuko\/15104","image":"https:\/\/pbs.twimg.com\/profile_images\/892733112500629504\/qUWLNjwz_normal.jpg","description":"\u5185\u79d1\u533b\u300250\u4ee3\u30fb\u662d\u548c\u751f\u307e\u308c\u3002\u5143\u67d0\u5973\u5b50\u5927\u6559\u6388\u3001\u73fe\u5728\u306f\u533b\u7642\u306b\u623b\u308a\u5185\u79d1\u30fb\u30ea\u30a6\u30de\u30c1\u8a3a\u7642\u3068\u5065\u8a3a\u3002\u307b\u307c\u96d1\u8ac7\u3002TW\u3084RT\u306f\u500b\u4eba\u306e\u898b\u89e3\u3002\u30bc\u30df\u30d6\u30ed\u30b0 http:\/\/msk-zemi.seesaa.net. : Rheumatology & Intern Med. Loves Fine Arts. Tweets R personal.","id_on_source":"k_masuko","tweeter_id":"135697598","geo":{"lt":35.6895,"ln":139.69171,"country":"JP"},"followers":878},"tweet_id":"376525070140575744"},{"url":"http:\/\/twitter.com\/LS_Medical\/status\/379712143542980609","license":"public","citation_ids":[1517019],"posted_on":"2013-09-16T21:03:24+00:00","author":{"name":"Living Safely","url":"http:\/\/www.LivingSafely.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1265326199\/LS_MedicalLogoSmall_normal.jpg","description":"Official page. We offer news and views aimed at the medical, dental, nursing, EMS and health related communities. We're part of Living http:\/\/Safely.org.","id_on_source":"LS_Medical","tweeter_id":"262389713","geo":{"lt":null,"ln":null},"followers":303},"tweet_id":"379712143542980609"},{"url":"http:\/\/twitter.com\/Darshanjagannat\/status\/385071327415394304","license":"datasift","citation_ids":[1517019],"posted_on":"2013-10-01T15:58:53+00:00","author":{"name":"Darshan jagannath","image":"http:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_3_normal.png","description":"","id_on_source":"Darshanjagannat","tweeter_id":"597117720","followers":6},"tweet_id":"385071327415394304"},{"url":"http:\/\/twitter.com\/LS_Medical\/status\/393520142812217344","license":"datasift","citation_ids":[1517019],"posted_on":"2013-10-24T23:31:27+00:00","author":{"name":"Living Safely","url":"http:\/\/www.LivingSafely.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1265326199\/LS_MedicalLogoSmall_normal.jpg","description":"Official page. We offer news and views aimed at the medical, dental, nursing, EMS and health related communities. We're part of Living http:\/\/Safely.org.","id_on_source":"LS_Medical","tweeter_id":"262389713","geo":{"lt":null,"ln":null},"followers":303},"tweet_id":"393520142812217344"},{"url":"http:\/\/twitter.com\/LS_Medical\/status\/395256598488440833","license":"public","citation_ids":[1517019],"posted_on":"2013-10-29T18:31:31+00:00","author":{"name":"Living Safely","url":"http:\/\/www.LivingSafely.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1265326199\/LS_MedicalLogoSmall_normal.jpg","description":"Official page. We offer news and views aimed at the medical, dental, nursing, EMS and health related communities. We're part of Living http:\/\/Safely.org.","id_on_source":"LS_Medical","tweeter_id":"262389713","geo":{"lt":null,"ln":null},"followers":303},"tweet_id":"395256598488440833"},{"url":"http:\/\/twitter.com\/AnnemarieVtW\/statuses\/339666136671068161","license":"public","citation_ids":[1517019],"posted_on":"2013-05-29T08:54:52+00:00","author":{"name":"A. Vroom - Ten Wolde","url":"http:\/\/nl.linkedin.com\/in\/annemarievroomtenwolde","image":"https:\/\/pbs.twimg.com\/profile_images\/1118347634\/Annemarie-photo_normal.png","description":"PhD Organic Chemistry; Science Writer #Biotech\/#Pharma #biologics #biosimilars #antibody #mAbs #ADCs #bispecifics #biobetters #health #chemistry","id_on_source":"AnnemarieVtW","tweeter_id":"185567498","geo":{"lt":52.5,"ln":5.75,"country":"NL"},"followers":2239},"tweet_id":"339666136671068161"},{"url":"https:\/\/twitter.com\/ELECTOR_eHealth\/status\/568763001664344065","license":"datasift","rt":["ARD_BMJ"],"citation_ids":[1517019],"posted_on":"2015-02-20T13:24:01+00:00","author":{"name":"ELECTOR","image":"https:\/\/pbs.twimg.com\/profile_images\/565455474862997504\/oli2pGiE_normal.png","id_on_source":"ELECTOR_eHealth","tweeter_id":"3029938077","geo":{"lt":55.67594,"ln":12.56553,"country":"DK"},"followers":74},"tweet_id":"568763001664344065"},{"url":"https:\/\/twitter.com\/chandini_rao\/status\/569051872025288704","license":"datasift","rt":["ARD_BMJ"],"citation_ids":[1517019],"posted_on":"2015-02-21T08:31:53+00:00","author":{"name":"Chandini Rao","image":"https:\/\/pbs.twimg.com\/profile_images\/875822457843798017\/TD0O7iqR_normal.jpg","description":"Rheumatologist, Training Programme Director, veg-grower, twitcher & Glastonbury obsessive. Views are my own","id_on_source":"chandini_rao","tweeter_id":"1379150396","geo":{"lt":52.73213,"ln":-1.43166,"country":"GB"},"followers":187},"tweet_id":"569051872025288704"},{"url":"https:\/\/twitter.com\/ElenaNikiUK\/status\/569046083000799232","license":"datasift","rt":["ARD_BMJ"],"citation_ids":[1517019],"posted_on":"2015-02-21T08:08:53+00:00","author":{"name":"Elena Nikiphorou","image":"https:\/\/pbs.twimg.com\/profile_images\/478251874584240129\/gIy3Py7o_normal.jpeg","description":"Rheumatologist, London. Interests: RA: treatments & outcomes; Epidemiology. @ARD_BMJ and @EMEUNET contributor Classical music-piano playing, dancing, travelling","id_on_source":"ElenaNikiUK","tweeter_id":"2569488493","geo":{"lt":54.75844,"ln":-2.69531,"country":"GB"},"followers":1849},"tweet_id":"569046083000799232"},{"url":"https:\/\/twitter.com\/nostrobardo\/status\/608393342771175424","license":"datasift","rt":["ARD_BMJ"],"citation_ids":[1517019],"posted_on":"2015-06-09T22:00:50+00:00","author":{"name":"Lou","image":"http:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_3_normal.png","id_on_source":"nostrobardo","tweeter_id":"2233838638","followers":681},"tweet_id":"608393342771175424"},{"url":"https:\/\/twitter.com\/ARD_BMJ\/status\/568747152274530305","license":"datasift","citation_ids":[1517019],"posted_on":"2015-02-20T12:21:02+00:00","author":{"name":"ARD","url":"http:\/\/ard.bmj.com","image":"https:\/\/pbs.twimg.com\/profile_images\/784372806297460737\/0G3PFep__normal.jpg","description":"ARD is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange. Top impact factor in the rheumatology field","id_on_source":"ARD_BMJ","tweeter_id":"138744646","geo":{"lt":null,"ln":null},"followers":3203},"tweet_id":"568747152274530305"},{"url":"http:\/\/twitter.com\/psufka\/status\/381880896988516352","license":"public","rt":["PhilipGardiner"],"citation_ids":[1517019],"posted_on":"2013-09-22T20:41:15+00:00","author":{"name":"Dr. Paul Sufka","url":"http:\/\/paulsufka.com","image":"https:\/\/pbs.twimg.com\/profile_images\/708647790889447424\/xMQSftWb_normal.jpg","description":"Rheumatologist | Startup Advisor | Health Tech | Fitness | \u2615\ufe0f \ud83e\udd53 | @RheumJC","id_on_source":"psufka","tweeter_id":"16553366","geo":{"lt":46.25024,"ln":-94.25055,"country":"US"},"followers":3481},"tweet_id":"381880896988516352"},{"url":"http:\/\/twitter.com\/PhilipGardiner\/status\/381873915683143681","license":"datasift","citation_ids":[1517019],"posted_on":"2013-09-22T20:13:31+00:00","author":{"name":"Philip Gardiner","url":"http:\/\/www.philipgardiner.me.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/539925866873372672\/SZHZpKEE_normal.jpeg","description":"I'm a Rheumatologist in N. Ireland: I tweet mostly about medicine & health tech. Views my own. I also share some of my wife's great photos! Views are my own.","id_on_source":"PhilipGardiner","tweeter_id":"57893412","geo":{"lt":54.9981,"ln":-7.30934,"country":"GB"},"followers":2212},"tweet_id":"381873915683143681"},{"url":"http:\/\/twitter.com\/PhilipGardiner\/status\/381874555637469184","license":"public","citation_ids":[1517019],"posted_on":"2013-09-22T20:16:03+00:00","author":{"name":"Philip Gardiner","url":"http:\/\/www.philipgardiner.me.uk","image":"https:\/\/pbs.twimg.com\/profile_images\/539925866873372672\/SZHZpKEE_normal.jpeg","description":"I'm a Rheumatologist in N. Ireland: I tweet mostly about medicine & health tech. Views my own. I also share some of my wife's great photos! Views are my own.","id_on_source":"PhilipGardiner","tweeter_id":"57893412","geo":{"lt":54.9981,"ln":-7.30934,"country":"GB"},"followers":2212},"tweet_id":"381874555637469184"}],"news":[{"title":"Celltrion Healthcare Six posters on clinical experience with biosimilar mAb infliximab presented at European Crohns and Colitis Organisation ECCO 10th annual congress","url":"http:\/\/www.bioportfolio.com\/news\/article\/2235562\/Celltrion-Healthcare-Six-posters-on-clinical-experience-with-biosimilar-mAb-infliximab-presented.html","license":"public","citation_ids":[1517019,1517025],"posted_on":"2015-02-19T23:01:00+00:00","summary":"Celltrion Healthcare has today announced data demonstrating that the worlds first biosimilar monoclonal antibody mAb infliximab is an effective treatment option for patients with the chronic debilitating autoimmune diseases Crohns d...","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Celltrion Healthcare: seis presentaciones de p\u00f3ster sobre la experiencia cl\u00ednica con el mAb biosimilar infliximab durante el 10\u00ba Congreso anual de la Organizaci\u00f3n Europea de Crohn y Colitis (ECCO)","url":"http:\/\/noticias.lainformacion.com\/ciencia-y-tecnologia\/biotecnologia\/celltrion-healthcare-seis-presentaciones-de-poster-sobre-la-experiencia-clinica-con-el-mab-biosimilar-infliximab-durante-el-10o-congreso-anual-de-la-organizacion-europea-de-crohn-y-colitis-ecco_cl5pSNSL6ovJpyhiJNe6I2\/","license":"public","citation_ids":[1517019,1517025],"posted_on":"2015-02-20T08:55:00+00:00","summary":"Celltrion Healthcare ha anunciado los datos que demuestran que el primer anticuerpo monoclonal biosimilar (mAb) del mundo ,infliximab, es una opci\u00f3n de tratamiento eficaz para los pacientes con enfermedades cr\u00f3nicas autoinmunes y deblitantes, enfermedad de","author":{"name":"Lainformacion.com ","url":"http:\/\/www.lainformacion.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/017\/normal\/Screen_Shot_2014-07-07_at_14.50.59.png?1404741128"}},{"title":"Celltrion f\u00fchrt weltweit ersten monoklonalen Biosimilar-Antik\u00f6rper Remsima\u2122 in 12 neuen europ\u00e4ischen M\u00e4rkten ein","url":"http:\/\/www.ad-hoc-news.de\/celltrion-fuehrt-weltweit-ersten-monoklonalen-biosimilar-antikoerper-remsima-in-12-neuen--\/de\/News\/42155591","license":"public","citation_ids":[1517019,1517025],"posted_on":"2015-02-25T06:14:47+00:00","summary":"Celltrion Healthcare gab heute bekannt, dass Remsima\u2122 (Infliximab) in 12 europ\u00e4ischen M\u00e4rkten eingef\u00fchrt wird: Belgien, D\u00e4nemark, ...","author":{"name":"Ad Hoc News","url":"http:\/\/www.ad-hoc-news.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/201\/normal\/image.jpeg?1370251863"}},{"title":"Celltrion launches world's first biosimilar monoclonal antibody Remsima in 12 new European markets","url":"http:\/\/www.medicalnewstoday.com\/releases\/289957.php","license":"public","citation_ids":[1517019,1517025],"posted_on":"2015-02-26T10:00:00+00:00","summary":"Celltrion Healthcare has announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden...","author":{"name":"Medical News Today","url":"http:\/\/www.medicalnewstoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/040\/normal\/medical_news_today.png?1369846932"}},{"title":"Celltrion launches world\u2019s first biosimilar monoclonal antibody Remsima in 12 new European markets","url":"http:\/\/www.todaytopics.com\/celltrion-launches-worlds-first-biosimilar-monoclonal-antibody-remsima-in-12-new-european-markets\/34822\/","license":"public","citation_ids":[1517019,1517025],"posted_on":"2015-02-26T10:16:01+00:00","summary":"Celltrion Healthcare has announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. Remsima, developed by Celltrion, Inc., is the wo","author":{"name":"Today Topics ","url":"http:\/\/www.todaytopics.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/290\/normal\/Screen_Shot_2014-11-27_at_12.02.15.png?1417089747"}},{"title":"Celltrion lanza el primer anticuerpo monoclonal biosimilar del mundo, Remsima\u2122, en 12 nuevos mercados europeos","url":"http:\/\/noticias.lainformacion.com\/ciencia-y-tecnologia\/biotecnologia\/celltrion-lanza-el-primer-anticuerpo-monoclonal-biosimilar-del-mundo-remsima-en-12-nuevos-mercados-europeos_Hx4qTPzkt0mseJpvQSkpj\/","license":"public","citation_ids":[1517019,1517025],"posted_on":"2015-02-25T09:57:00+00:00","summary":"Celltrion Healthcare ha anunciado el lanzamiento de Remsima\u2122 (infliximab) en 12 mercados europeos: Austria, B\u00e9lgica, Dinamarca, Francia, Alemania, Grecia, Italia, Luxemburgo, Holanda, Espa\u00f1a, Suecia y Reino Unido. Remsima\u2122, desarrollado por Celltrion, Inc.","author":{"name":"Lainformacion.com ","url":"http:\/\/www.lainformacion.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/017\/normal\/Screen_Shot_2014-07-07_at_14.50.59.png?1404741128"}},{"title":"Biosimilar of Remicade Works in Ankylosing Spondylitis","url":"http:\/\/ct.moreover.com\/?a=24255232137&p=1pl&v=1&x=L2DXbcqQ9XkAJm_5lLmbDA","license":"public","citation_ids":[5021879,1517019,4684394],"posted_on":"2016-01-27T13:30:00+00:00","summary":"Action Points CT-P13, a biosimilar of infliximab (Remicade), demonstrated comparable and durable efficacy in the treatment of ankylosing spondylitis.","author":{"name":"MedPage Today","url":"http:\/\/www.medpagetoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/262\/normal\/Screen_Shot_2016-02-09_at_10.51.03.png?1455015082"}},{"title":"Celltrion Healthcare: Switching to Remsima\u00ae\u25bc (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies","url":"http:\/\/ct.moreover.com\/?a=25855915949&p=1pl&v=1&x=Nx78M5divzkyITDmCEWOlQ","license":"public","citation_ids":[1517019,1517025],"posted_on":"2016-03-18T11:20:00+00:00","summary":"Physician view of monoclonal antibody biosimilars increasingly positive as real-world evidence and experience grows AMSTERDAM--(BUSINESS WIRE)-- Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show\u2026","author":{"name":"CNBC","url":"http:\/\/www.cnbc.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/411\/normal\/Screen_Shot_2016-01-12_at_14.43.08.png?1452609805"}},{"title":"Celltrion Healthcare: Switching to Remsima\u00ae? (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies","url":"http:\/\/ct.moreover.com\/?a=25855936388&p=1pl&v=1&x=FmOuXVqTYDloUmWCfM8hHw","license":"public","citation_ids":[1517019,1517025],"posted_on":"2016-03-18T11:22:50+00:00","summary":"Celltrion Healthcare: Switching to Remsima\u00ae\u25bc (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies Physician view of monoclonal antibody biosimilars increasingly positive as real-world evidence and\u2026","author":{"name":"Bloomberg","url":"http:\/\/www.bloomberg.com\/europe","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/659\/normal\/Screen_Shot_2016-01-26_at_12.11.18.png?1453810324"}},{"title":"Celltrion Healthcare: Switching to Remsima\u00ae\u25bc (infliximab) from originator has no negative effect on safety or efficacy in 10 real-world studies","url":"http:\/\/ct.moreover.com\/?a=25855943674&p=1pl&v=1&x=Fg6fDxjsjGAFvvSA5P5DKA","license":"public","citation_ids":[1517019,1517025],"posted_on":"2016-03-18T11:20:00+00:00","summary":"Physician view of monoclonal antibody biosimilars increasingly positive as real-world evidence and experience grows Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"Celltrion Healthcare: Switching to Remsima\u00ae\u25bc (infliximab) from originator has no negative effect on safety \u2026","url":"http:\/\/ct.moreover.com\/?a=25855980581&p=1pl&v=1&x=vELqpgBZe7czyukprFailQ","license":"public","citation_ids":[1517019,1517025],"posted_on":"2016-03-18T11:27:53+00:00","summary":"Physician view of monoclonal antibody biosimilars increasingly positive as real-world evidence and experience grows Celltrion Healthcare 7 minutes ago AMSTERDAM--(BUSINESS WIRE)-- Real-world studies with nearly 600 inflammatory bowel disease (IBD\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"Celltrion launches worlds first biosimilar monoclonal antibody Remsima in 12 new European markets","url":"http:\/\/www.bioportfolio.com\/news\/article\/2240428\/Celltrion-launches-worlds-first-biosimilar-monoclonal-antibody-Remsima-in-12-new-European.html","license":"public","citation_ids":[1517019,1517025],"posted_on":"2015-02-24T23:01:00+00:00","summary":"Now available in 31 countries for the treatment of autoimmune diseases Celltrion Healthcare has today announced the launch of Remsima infliximab in 12 European markets Austria Belgium Denmark France Germany Greece Italy Lux...","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}}],"facebook":[{"url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=922975707747412&id=147927835252207","license":"public","citation_ids":[1517019],"posted_on":"2015-02-20T12:21:03+00:00","summary":"The #AS PK study contributing to infliximab biosimliar approval, marketed this week in Europe http:\/\/buff.ly\/1F2dVrP","author":{"name":"Annals of the Rheumatic Diseases (ARD)","url":"https:\/\/www.facebook.com\/147927835252207","facebook_wall_name":"Annals of the Rheumatic Diseases (ARD)","image":"https:\/\/graph.facebook.com\/147927835252207\/picture","id_on_source":"147927835252207"}},{"title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=571187686259551&id=147927835252207","license":"public","citation_ids":[1517019],"posted_on":"2013-05-17T20:43:13+00:00","summary":"ObjectivesTo compare the pharmacokinetics (PK), safety and efficacy of innovator infliximab (INX) and CT-P13, a biosimilar to INX, in patients with active ankylosing spondylitis (AS). MethodsPhase 1 randomised, double-blind, multicentre, \u2026","author":{"name":"Annals of the Rheumatic Diseases (ARD)","url":"https:\/\/www.facebook.com\/147927835252207","facebook_wall_name":"Annals of the Rheumatic Diseases (ARD)","image":"https:\/\/graph.facebook.com\/147927835252207\/picture","id_on_source":"147927835252207"}}],"googleplus":[{"title":"Review of the Article: A randomised, double-blinded, multicentre, parallel-group, prospective study ...","url":"https:\/\/plus.google.com\/+MultipharmaInternational\/posts\/YDiLvzFJ4F8","license":"public","citation_ids":[1517019],"posted_on":"2014-06-27T08:21:51+00:00","summary":"Review of the Article: A randomised, double-blinded, multicentre, parallel-group, prospective study ... Review of the Article:A randomised, double-blinded, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy o"}]}}